| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »


Results 1 - 1 out of 1 displayed.
Search filter:
  • Search for: Company
Sort direction:
Sort direction:
 |   |   | 
Cambridge, Massachusetts, USA
Main sector:
  • Pharma (fully integrated)
  • Antibodies
  • Biosimilars
  • Gene therapy
  • Nucleic acid drugs
  • Proteins
  • Small molecule therapeutics
  • Cardiovascular / cardiology
  • Congenital malformations, deformations and chromosomal abnormalities / medical genetics
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Genitourinary system / Urology
  • Mental and behavioural disorders / psychiatry /psychology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
  • Worldwide: 7,570
  • In development: 21
  • On the market: 9
Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. The company has a portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and is providing the first and only approved treatment to address a defining pathology of alzheimer’s disease. The company's product AVONEX is for the treatment of relapsing forms of...

Already have a valid Biotechgate account? Login here »

Get access to Biotechgate

Download complete company profiles including product pipelines, financing rounds and management details.

to the top ↑